SCHEMBL14228296

SCHEMBL14228296

Cc1ccc(C(C)C)cc1N1CCOCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
NSD2 O96028 1/20 0.46
ALDH1A1 P00352 2/20 0.43
ALOX15 P16050 2/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPT P10636 2/20 0.43
GAA P10253 1/20 0.43
ALOX12 P18054 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
KCNH2 Q12809 1/20 0.43
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
TRPA1 O75762 1/20 0.42
PTGS1 P23219 1/20 0.42
CACNA1C Q13936 1/20 0.42
NPC1 O15118 2/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13450397 0.87 ALDH1A1 (0.48) LMNAL3MBTL1NSD2ALDH1A1ALOX15
SCHEMBL12074844 0.84 LMNA (0.52) LMNAL3MBTL1ALDH1A1MAPTGAA
SCHEMBL14200387 0.83 NPC1 (0.44) LMNAL3MBTL1ALDH1A1ALOX15KDM4E
SCHEMBL14200352 0.83 MAPT (0.43) LMNAL3MBTL1ALDH1A1ALOX15KDM4E
SCHEMBL14614571 0.82 CYP3A4 (0.53) LMNAL3MBTL1ALDH1A1ALOX15KDM4E
SCHEMBL25870772 0.82 LGMN (0.61) LMNAL3MBTL1ALDH1A1ALOX15KDM4E
SCHEMBL16939771 0.81 LMNA (0.44) LMNAL3MBTL1ALDH1A1KDM4EMAPT
SCHEMBL21968821 0.81 ALDH1A1 (0.46) LMNAL3MBTL1ALDH1A1ALOX15KDM4E
SCHEMBL22296418 0.80 MAPT (0.58) LMNAL3MBTL1ALDH1A1ALOX15KDM4E
SCHEMBL22422339 0.80 ADRB1 (0.54) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312564-A1 AROMATIC RING-LACTAM COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI RINGENE BIOPHARMA CO., LTD. (CN) 2023-10-05 US disclosed
EP-3122353-B1 SUBSTITUTED INDOLE MCL-1 INHIBITORS UNIV VANDERBILT (US) 2020-10-28 EP disclosed
WO-2017193023-A1 ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME MELINTA THERAPEUTICS, INC. (US) 2017-11-09 WO disclosed
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria SHIONOGI & CO., LTD. (JP) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312564-A1 AROMATIC RING-LACTAM COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF WEE1, WEE2, WASF2 LMNA 2779/4885L3MBTL1 4104/4885NSD2 3581/4885
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria CSGALNACT1, MON2, NR2C2 LMNA 4466/4885L3MBTL1 3585/4885NSD2 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.